Literature DB >> 19563890

Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Julianne E Rollenhagen1, Anuj Kalsy, Rina Saksena, Alaullah Sheikh, Mohammad Murshid Alam, Firdausi Qadri, Stephen B Calderwood, Pavol Kovác, Edward T Ryan.   

Abstract

Antibodies specific for Vibrio cholerae lipopolysaccaride (LPS) are common in humans recovering from cholera, and constitute a primary component of the vibriocidal response, a serum complement-mediated bacteriocidal response correlated with protection against cholera. In order to determine whether transcutaneous immunization (TCI) with a V. cholerae neoglycoconjugate (CHO-BSA) comprised of a synthetic terminal hexasaccharide of the O-specific polysaccharide of V. cholerae O1 (Ogawa) conjugated with bovine serum albumin (BSA) could induce anti-V. cholerae LPS and vibriocidal responses, we applied CHO-BSA transcutaneously in the presence or absence of the immune adjuvant cholera toxin (CT) to mice. Transcutaneously applied neoglycoconjugate elicited prominent V. cholerae specific LPS IgG responses in the presence of CT, but not IgM or IgA responses. CT applied on the skin induced strong IgG and IgA serum responses. TCI with neoglycoconjugate did not elicit detectable vibriocidal responses, protection in a mouse challenge assay, or stool anti-V. cholerae IgA responses, irrespective of the presence or absence of CT. Our results suggest that transcutaneously applied synthetic V. cholerae neoglycoconjugate is safe and immunogenic, but predominantly induces systemic LPS responses of the IgG isotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563890      PMCID: PMC2761657          DOI: 10.1016/j.vaccine.2009.06.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  43 in total

1.  Serotype cycles in cholera dynamics.

Authors:  Katia Koelle; Mercedes Pascual; Md Yunus
Journal:  Proc Biol Sci       Date:  2006-11-22       Impact factor: 5.349

2.  Skin immunization made possible by cholera toxin.

Authors:  G M Glenn; M Rao; G R Matyas; C R Alving
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

3.  Effect of saccharide length on the immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio cholerae O1, serotype Ogawa.

Authors:  Rina Saksena; Xingquan Ma; Terri K Wade; Pavol Kovác; William F Wade
Journal:  Carbohydr Res       Date:  2005-10-17       Impact factor: 2.104

4.  Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Francisca Cerda; Manohar John; Jason B Harris; Regina C Larocque; Firdausi Qadri; Stephen B Calderwood; Ronald K Taylor; Edward T Ryan
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

5.  Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.

Authors:  F Qadri; C Wennerås; M J Albert; J Hossain; K Mannoor; Y A Begum; G Mohi; M A Salam; R B Sack; A M Svennerholm
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

6.  Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1, Ogawa hexasaccharide neoglycoconjugates.

Authors:  Rina Saksena; Xingquan Ma; Terri K Wade; Pavol Kovác; William F Wade
Journal:  FEMS Immunol Med Microbiol       Date:  2006-06

7.  Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants.

Authors:  G M Glenn; T Scharton-Kersten; R Vassell; G R Matyas; C R Alving
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

8.  Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity.

Authors:  Jason B Harris; Ashraful I Khan; Regina C LaRocque; David J Dorer; Fahima Chowdhury; Abu S G Faruque; David A Sack; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

9.  Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.

Authors:  G M Glenn; T Scharton-Kersten; R Vassell; C P Mallett; T L Hale; C R Alving
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

10.  Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A.

Authors:  Terri K Wade; Rina Saksena; Joseph Shiloach; Pavol Kovác; William F Wade
Journal:  FEMS Immunol Med Microbiol       Date:  2006-09-29
View more
  16 in total

1.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

2.  Insights from natural infection-derived immunity to cholera instruct vaccine efforts.

Authors:  Marcela F Pasetti; Myron M Levine
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

Review 3.  Vibrio cholerae: lessons for mucosal vaccine design.

Authors:  Anne L Bishop; Andrew Camilli
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

4.  Virus-like Particle Display of Vibrio cholerae O-Specific Polysaccharide as a Potential Vaccine against Cholera.

Authors:  Zahra Rashidijahanabad; Meagan Kelly; Mohammad Kamruzzaman; Firdausi Qadri; Taufiqur R Bhuiyan; Hunter McFall-Boegeman; Di Wu; Grzegorz Piszczek; Peng Xu; Edward T Ryan; Xuefei Huang
Journal:  ACS Infect Dis       Date:  2022-02-16       Impact factor: 5.578

5.  A Self-Assembling Whole-Cell Vaccine Antigen Presentation Platform.

Authors:  Julie Liao; Daniel R Smith; Jóhanna Brynjarsdóttir; Paula I Watnick
Journal:  J Bacteriol       Date:  2018-07-10       Impact factor: 3.490

6.  Mapping the glycation sites in the neoglycoconjugate from hexasaccharide antigen of Vibrio cholerae, serotype Ogawa and the recombinant tetanus toxin C-fragment carrier.

Authors:  Farid Jahouh; Peng Xu; Willie F Vann; Pavol Kováč; Joseph H Banoub
Journal:  J Mass Spectrom       Date:  2013-10       Impact factor: 1.982

7.  Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.

Authors:  A A Tarique; A Kalsy; M Arifuzzaman; S M Rollins; R C Charles; D T Leung; J B Harris; R C Larocque; A Sheikh; M S Bhuiyan; R Saksena; J D Clements; S B Calderwood; F Qadri; P Kovác; E T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-02-22

8.  A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice.

Authors:  Md Abu Sayeed; Meagan Kelly Bufano; Peng Xu; Grace Eckhoff; Richelle C Charles; Mohammad Murshid Alam; Tania Sultana; Md Rasheduzzaman Rashu; Amanda Berger; Geoffrey Gonzalez-Escobedo; Anjali Mandlik; Taufiqur Rahman Bhuiyan; Daniel T Leung; Regina C LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; W F Vann; Pavol Kováč; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2015-07-08

9.  Development of a new dipstick (Cholkit) for rapid detection of Vibrio cholerae O1 in acute watery diarrheal stools.

Authors:  Md Abu Sayeed; Kamrul Islam; Motaher Hossain; Noor Jahan Akter; Md Nur Alam; Nishat Sultana; Farhana Khanam; Meagan Kelly; Richelle C Charles; Pavol Kováč; Peng Xu; Jason R Andrews; Stephen B Calderwood; Jakia Amin; Edward T Ryan; Firdausi Qadri
Journal:  PLoS Negl Trop Dis       Date:  2018-03-14

10.  Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide.

Authors:  Mohammad Murshid Alam; Megan Kelly Bufano; Peng Xu; Anuj Kalsy; Y Yu; Y Wu Freeman; Tania Sultana; Md Rasheduzzaman Rashu; Ishaan Desai; Grace Eckhoff; Daniel T Leung; Richelle C Charles; Regina C LaRocque; Jason B Harris; John D Clements; Stephen B Calderwood; Firdausi Qadri; W F Vann; Pavol Kováč; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2014-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.